Are you interested in the Specific Challenges and Optimization of NGS for HLA?
Join us online for a presentation by Tim Hague and Craig Funnell and learn more about an assay and software for whole-gene consensus generation for HLA Genotyping – characterized by simplicity, balanced alleles and even coverage. The webinar will include a demo on the advanced features of our HLA Twin Software.
Our special special guest speaker, Prof. Dimitri Monos from The Children’s Hospital of Philadelphia, who uses Holotype HLA™ in a routine, clinical practice, will introduce his experience with the Holotype HLA assay development and the specific challenges of NGS.
| Date: | Tuesday, 30th June, 2015 |
| Time: | 11am–12pm EST (4–5pm CET) A live Q&A session will follow the presentation, offering you the opportunity to put forward any questions. Following registration, you will receive a confirmation email containing information for joining this event. This Webinar will be recorded and material is available on request. |
- Introduction & Benefits of NGS
- Our Experience with the Holotype HLA Assay Development
- Specific Challenges of NGS
- HLA Twin Software Overview, Live Demo
- Advanced Features for Software Optimization, within Demo
- Summary & Benefits
- Q&A Session
Presenters
Dimitri S. Monos, Ph.D. (The Children’s Hospital of Philadelphia)
Dr. Monos is the Director of Immunogenetics Laboratory at The Children’s Hospital of Philadelphia and Professor of Pathology and Lab Medicine at Perelman School of Medicine, University of Pennsylvania, USA. His research interests cover a wide spectrum of HLA-related topics. His lab has pioneered the DNA-based methodologies for HLA typing and more recently the introduction of Next Generation Sequencing in the field of Immunogenetics, worked on a number of structure/function relationships of HLAs, contributed in identifying the exact structural elements on the different HLA molecules associated with several autoimmune diseases and through genome-wide association studies identify additional genomic regions associated with autoimmunity. His work has been funded by NIH, ADA, JDF, University of Pennsylvania, The Children’s Hospital of Philadelphia, Diabetes Research and Education Foundation, National Marrow Donor Program and other foundations. He has authored more than 100 original publications in international journals (including Nature and Νature Genetics). He served on the editorial boards of several journals and as ad hoc reviewer in 20 journals (including NEJM and Nature). Dr. Monos has been invited to present his work at different Universities, National and International meetings. He has also participated in Study Sections reviewing grants for NIH, NMDP, University of Pennsylvania and The Children’s Hospital of Philadelphia.
Tim Hague (CEO, Omixon)
A passionate biotechnology executive combining a science education with a strong IT background. Tim joined Omixon as a Software Architect before swiftly taking on the role of CTO, a position he held for more than 3 years. In 2013 he became Omixon’s CEO, adding world-wide responsibility for sales, marketing, HR and finances to his existing leadership of research and development. Before joining Omixon, he accumulated 15 years of software engineering and design expertise as Architect/Design Lead at Lufthansa Systems, Technical Consultant at iE and Technical Team Leader at IBM, among others. Tim received a BSc in Genetics from Nottingham University and an MSc in Information Systems Design from the University of Westminster.
Craig Funnell (Director, Sales & Marketing, Omixon)
Experienced international Sales, Business Development and Marketing Executive. Before moving to Life Science, Craig spent almost 20 years in the Professional Services sector, holding regional management positions with Aon Risk Solutions EMEA (Europe Middle East & Africa). Since 2010 Craig has been a Management Consultant, involved with a number of term projects; Information Technology, Engineering, Hi Tech and Life Sciences – including; Interim CEO of Dyntell Software, Interim CEO of ThalesNano Nanotechnology Inc, consultant for DAVID Spine Clinic and ChemAxon Cheminformatics. Craig initially joined Omixon with a Sales & Marketing consultancy role, and now heads up our worldwide Revenue Generation efforts.
